Can a pulsatile drug schedule beat brain metastases in lung cancer?
NCT ID NCT07348965
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial is testing a higher, every-other-day dose of the drug furmonertinib in people with a specific type of lung cancer (EGFR-mutant NSCLC) that has spread to the lining of the brain and spinal cord (leptomeningeal metastasis). The study will compare this high-dose schedule to the standard daily dose to see if it controls the disease better and has acceptable side effects. About 42 participants will choose or be assigned to one of the two dosing schedules and be followed until their disease worsens or side effects become too severe.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
furmonertinib
What this could lead to
If it works, this could offer a more effective way to control NSCLC that has spread to the brain and spinal cord lining, potentially improving survival and quality of life.
What could go wrong
This is a small, early-phase study with only 42 participants, so results may not apply broadly. High-dose regimens can also cause more side effects, and the drug may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial Hospital of Chinese Medicine
RECRUITINGGuangzhou, Guangdong, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••